Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVRO
CUSIPN/A
Phone650-251-0005
Debt
Debt-to-Equity Ratio0.61
Current Ratio7.99
Quick Ratio6.17
Price-To-Earnings
Trailing P/E Ratio-48.36
Forward P/E Ratio-47.89
P/E GrowthN/A
Sales & Book Value
Annual Sales$326.67 million
Price / Sales5.41
Cash FlowN/A
Price / CashN/A
Book Value$8.41 per share
Price / Book7.00
Profitability
EPS (Most Recent Fiscal Year)($1.25)
Net Income$-36,650,000.00
Net Margins-11.53%
Return on Equity-16.32%
Return on Assets-9.07%
Miscellaneous
Employees676
Outstanding Shares29,980,000
Market Cap$1,803.23
Nevro (NYSE:NVRO) Frequently Asked Questions
What is Nevro's stock symbol?
Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."
How were Nevro's earnings last quarter?
Nevro Corp (NYSE:NVRO) posted its quarterly earnings results on Thursday, February, 22nd. The medical equipment provider reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.01. The medical equipment provider earned $97.96 million during the quarter, compared to the consensus estimate of $96.87 million. Nevro had a negative return on equity of 16.32% and a negative net margin of 11.53%. The company's revenue for the quarter was up 38.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.34) EPS. View Nevro's Earnings History.
When is Nevro's next earnings date?
What price target have analysts set for NVRO?
10 Wall Street analysts have issued 12-month target prices for Nevro's shares. Their predictions range from $62.00 to $105.00. On average, they anticipate Nevro's share price to reach $84.5556 in the next twelve months. This suggests a possible upside of 43.6% from the stock's current price. View Analyst Ratings for Nevro.
What is the consensus analysts' recommendation for Nevro?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Nevro's key competitors?
Some companies that are related to Nevro include Hill-Rom (HRC), ICU Medical (ICUI), Globus Medical (GMED), Insulet (PODD), Haemonetics (HAE), Penumbra (PEN), Cantel Medical (CMD), Novocure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Luminex (LMNX), Glaukos (GKOS) and Tandem Diabetes Care (TNDM).
Who are Nevro's key executives?
Nevro's management team includes the folowing people:
- Mr. Rami Elghandour, Pres, CEO & Director (Age 39)
- Mr. Andrew H. Galligan, Chief Financial Officer (Age 62)
- Mr. Patrick Schmitz, VP of Operations (Age 58)
- Mr. James Alecxih, VP of Worldwide Sales (Age 53)
- Mr. Doug Alleavitch, VP of Quality (Age 57)
Has Nevro been receiving favorable news coverage?
News articles about NVRO stock have been trending somewhat negative on Thursday, according to Accern. The research group scores the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nevro earned a news sentiment score of -0.03 on Accern's scale. They also assigned news coverage about the medical equipment provider an impact score of 46.91 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Nevro's major shareholders?
Nevro's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (1.24%), Hardman Johnston Global Advisors LLC (0.32%), Bank of Montreal Can (0.10%), Essex Investment Management Co. LLC (0.03%) and Xact Kapitalforvaltning AB (0.01%). Company insiders that own Nevro stock include Andrew H Galligan, Doug Alleavitch, Michael Enxing, Michael F Demane, Rami Elghandour and Wilfred E Jaeger. View Institutional Ownership Trends for Nevro.
Which institutional investors are selling Nevro stock?
NVRO stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Hardman Johnston Global Advisors LLC. Company insiders that have sold Nevro company stock in the last year include Andrew H Galligan, Michael F Demane and Wilfred E Jaeger. View Insider Buying and Selling for Nevro.
Which institutional investors are buying Nevro stock?
NVRO stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Essex Investment Management Co. LLC and Xact Kapitalforvaltning AB. View Insider Buying and Selling for Nevro.
How do I buy shares of Nevro?
Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nevro's stock price today?
One share of NVRO stock can currently be purchased for approximately $58.90.
How big of a company is Nevro?
Nevro has a market capitalization of $1.80 billion and generates $326.67 million in revenue each year. The medical equipment provider earns $-36,650,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis. Nevro employs 676 workers across the globe.
How can I contact Nevro?
Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]
MarketBeat Community Rating for Nevro (NYSE NVRO)
MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe NVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
